| Linda Lawton, Dpm | |
|
1000 Smyrna Clayton Blvd, Suite 3, Smyrna, DE 19977-2228 | |
| (302) 659-0500 | |
| (302) 659-0590 |
| Full Name | Linda Lawton, Dpm |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot Surgery |
| Location | 1000 Smyrna Clayton Blvd, Smyrna, Delaware |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023296878 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0131X | Podiatrist - Foot Surgery | E10000133 (Delaware) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Linda Lawton, Dpm 1000 Smyrna Clayton Blvd, Suite 3, Smyrna, DE 19977-2228 Ph: (302) 659-0500 | Linda Lawton, Dpm 1000 Smyrna Clayton Blvd, Suite 3, Smyrna, DE 19977-2228 Ph: (302) 659-0500 |
News Archive
Older patients who happened to have been taking cholesterol-lowering statin drugs when admitted to the hospital with serious head injuries were 76 percent more likely to survive than those not taking the drugs, according to results of a Johns Hopkins study.
Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil) Extended-Release Tablets.
Preceyes B.V. (NL) and Nightstar (UK) have entered into a collaboration for the development of a high-precision drug delivery technology in the eye. Nightstar will use the Preceyes robotic device to further refine the delivery of gene therapy to the subretinal space for a range of inherited retinal diseases.
Making it easier to obtain emergency contraception would not increase unprotected intercourse, lead to abandonment of regular contraception, or increase the risk of sexually transmitted infections (STIs), according to a study in the January 5 issue of JAMA.
AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).
› Verified 7 days ago
Dr. Linda L Lawton, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 28 Deak Dr, Smyrna, DE 19977 Phone: 302-659-0500 Fax: 302-659-0590 | |
Dimitrios Moustakas, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 315 N Carter Rd, Smyrna, DE 19977 Phone: 302-730-4366 Fax: 302-730-0231 |